These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 17533046)
1. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046 [TBL] [Abstract][Full Text] [Related]
2. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955 [TBL] [Abstract][Full Text] [Related]
3. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413 [TBL] [Abstract][Full Text] [Related]
4. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390 [TBL] [Abstract][Full Text] [Related]
5. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147 [TBL] [Abstract][Full Text] [Related]
6. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560 [TBL] [Abstract][Full Text] [Related]
7. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672 [TBL] [Abstract][Full Text] [Related]
8. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. Britten CM; Meyer RG; Kreer T; Drexler I; Wölfel T; Herr W J Immunol Methods; 2002 Jan; 259(1-2):95-110. PubMed ID: 11730845 [TBL] [Abstract][Full Text] [Related]
9. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465 [TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718 [TBL] [Abstract][Full Text] [Related]
12. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Goddard RV; Prentice AG; Copplestone JA; Kaminski ER Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895 [TBL] [Abstract][Full Text] [Related]
13. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322 [TBL] [Abstract][Full Text] [Related]
14. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. Rivoltini L; Castelli C; Carrabba M; Mazzaferro V; Pilla L; Huber V; Coppa J; Gallino G; Scheibenbogen C; Squarcina P; Cova A; Camerini R; Lewis JJ; Srivastava PK; Parmiani G J Immunol; 2003 Oct; 171(7):3467-74. PubMed ID: 14500642 [TBL] [Abstract][Full Text] [Related]
15. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. Fournier S; Delespesse G; Rubio M; Biron G; Sarfati M J Clin Invest; 1992 Apr; 89(4):1312-21. PubMed ID: 1532590 [TBL] [Abstract][Full Text] [Related]
16. Selection of autologous CD4+ T-cells for adoptive T-cell substitution in patients with CD23+ B-cell CLL. Dettke M; Berger R; Jurko S; Mitterbauer G; Schwarzmeier JD; Höcker P Cytotherapy; 2002; 4(2):119-25. PubMed ID: 12006207 [TBL] [Abstract][Full Text] [Related]
17. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118 [TBL] [Abstract][Full Text] [Related]
18. Activation requirements of circulating antigen-specific human CD8(+) memory T cells probed with insect cell-based artificial antigen-presenting cells. Guelly C; Küpcü Z; Zalusky D; Karner M; Zehetner M; Schweighoffer T Eur J Immunol; 2002 Jan; 32(1):182-92. PubMed ID: 11754359 [TBL] [Abstract][Full Text] [Related]
20. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]